424 related articles for article (PubMed ID: 24899173)
1. MicroRNA miR-BART20-5p stabilizes Epstein-Barr virus latency by directly targeting BZLF1 and BRLF1.
Jung YJ; Choi H; Kim H; Lee SK
J Virol; 2014 Aug; 88(16):9027-37. PubMed ID: 24899173
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr Virus MicroRNA miR-BART20-5p Suppresses Lytic Induction by Inhibiting BAD-Mediated caspase-3-Dependent Apoptosis.
Kim H; Choi H; Lee SK
J Virol; 2016 Feb; 90(3):1359-68. PubMed ID: 26581978
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus miR-BART20-5p regulates cell proliferation and apoptosis by targeting BAD.
Kim H; Choi H; Lee SK
Cancer Lett; 2015 Jan; 356(2 Pt B):733-42. PubMed ID: 25449437
[TBL] [Abstract][Full Text] [Related]
4. Methylation profiling of Epstein-Barr virus immediate-early gene promoters, BZLF1 and BRLF1 in tumors of epithelial, NK- and B-cell origins.
Li L; Su X; Choi GC; Cao Y; Ambinder RF; Tao Q
BMC Cancer; 2012 Mar; 12():125. PubMed ID: 22458933
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr Virus miR-BHRF1-3 Targets the BZLF1 3'UTR and Regulates the Lytic Cycle.
Fachko DN; Chen Y; Skalsky RL
J Virol; 2022 Feb; 96(4):e0149521. PubMed ID: 34878852
[TBL] [Abstract][Full Text] [Related]
6. Viral genome methylation differentially affects the ability of BZLF1 versus BRLF1 to activate Epstein-Barr virus lytic gene expression and viral replication.
Wille CK; Nawandar DM; Panfil AR; Ko MM; Hagemeier SR; Kenney SC
J Virol; 2013 Jan; 87(2):935-50. PubMed ID: 23135711
[TBL] [Abstract][Full Text] [Related]
7. Cellular immediate-early gene expression occurs kinetically upstream of Epstein-Barr virus bzlf1 and brlf1 following cross-linking of the B cell antigen receptor in the Akata Burkitt lymphoma cell line.
Ye J; Gradoville L; Miller G
J Virol; 2010 Dec; 84(23):12405-18. PubMed ID: 20861250
[TBL] [Abstract][Full Text] [Related]
8. Cellular transcription factor Oct-1 interacts with the Epstein-Barr virus BRLF1 protein to promote disruption of viral latency.
Robinson AR; Kwek SS; Hagemeier SR; Wille CK; Kenney SC
J Virol; 2011 Sep; 85(17):8940-53. PubMed ID: 21697476
[TBL] [Abstract][Full Text] [Related]
9. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors.
Feng WH; Westphal E; Mauser A; Raab-Traub N; Gulley ML; Busson P; Kenney SC
J Virol; 2002 Nov; 76(21):10951-9. PubMed ID: 12368338
[TBL] [Abstract][Full Text] [Related]
10. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
Westphal EM; Mauser A; Swenson J; Davis MG; Talarico CL; Kenney SC
Cancer Res; 1999 Apr; 59(7):1485-91. PubMed ID: 10197618
[TBL] [Abstract][Full Text] [Related]
11. Rescue of the Epstein-Barr virus BZLF1 mutant, Z(S186A), early gene activation defect by the BRLF1 gene product.
Adamson AL; Kenney SC
Virology; 1998 Nov; 251(1):187-97. PubMed ID: 9813214
[TBL] [Abstract][Full Text] [Related]
12. Molecular Basis of Epstein-Barr Virus Latency Establishment and Lytic Reactivation.
Murata T; Sugimoto A; Inagaki T; Yanagi Y; Watanabe T; Sato Y; Kimura H
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960613
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus (EBV) EB1/Zta protein provided in trans and competent for the activation of productive cycle genes does not activate the BZLF1 gene in the EBV genome.
Le Roux F; Sergeant A; Corbo L
J Gen Virol; 1996 Mar; 77 ( Pt 3)():501-9. PubMed ID: 8601788
[TBL] [Abstract][Full Text] [Related]
14. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Ye J; Gradoville L; Daigle D; Miller G
J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
[TBL] [Abstract][Full Text] [Related]
15. Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression.
Li Y; Webster-Cyriaque J; Tomlinson CC; Yohe M; Kenney S
J Virol; 2004 Apr; 78(8):4197-206. PubMed ID: 15047835
[TBL] [Abstract][Full Text] [Related]
16. 5-hydroxymethylation of the EBV genome regulates the latent to lytic switch.
Wille CK; Nawandar DM; Henning AN; Ma S; Oetting KM; Lee D; Lambert P; Johannsen EC; Kenney SC
Proc Natl Acad Sci U S A; 2015 Dec; 112(52):E7257-65. PubMed ID: 26663912
[TBL] [Abstract][Full Text] [Related]
17. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes.
Ragoczy T; Heston L; Miller G
J Virol; 1998 Oct; 72(10):7978-84. PubMed ID: 9733836
[TBL] [Abstract][Full Text] [Related]
18. Nuclear factor-Y and Epstein Barr virus in nasopharyngeal cancer.
Chia MC; Leung A; Krushel T; Alajez NM; Lo KW; Busson P; Klamut HJ; Bastianutto C; Liu FF
Clin Cancer Res; 2008 Feb; 14(4):984-94. PubMed ID: 18281530
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.
Wen W; Iwakiri D; Yamamoto K; Maruo S; Kanda T; Takada K
J Virol; 2007 Jan; 81(2):1037-42. PubMed ID: 17079287
[TBL] [Abstract][Full Text] [Related]
20. Editing of Epstein-Barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency.
Iizasa H; Wulff BE; Alla NR; Maragkakis M; Megraw M; Hatzigeorgiou A; Iwakiri D; Takada K; Wiedmer A; Showe L; Lieberman P; Nishikura K
J Biol Chem; 2010 Oct; 285(43):33358-33370. PubMed ID: 20716523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
